or Try an Advanced Search...

    Technical Analysis for MLYS - Mineralys Therapeutics, Inc.

    Grade Last Price % Change Price Change
    B 12.77 2.82% 0.35
    MLYS closed up 2.82 percent on Friday, May 31, 2024, on 1.63 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical MLYS trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Up 3 Days in a Row Strength 0.00%
    Pocket Pivot Bullish Swing Setup 2.82%
    Oversold Stochastic Weakness 2.82%
    Gapped Down Weakness 3.74%
    Oversold Stochastic Weakness 3.74%
    Outside Day Range Expansion 5.02%
    Gapped Up Strength 5.02%
    Down 3 Days in a Row Weakness 5.02%
    Older End-of-Day Signals for MLYS ...

       Recent Intraday Alerts

    Alert Time
    Possible Pocket Pivot 1 day ago
    60 Minute Opening Range Breakdown 1 day ago
    2x Volume Pace 1 day ago
    50 DMA Resistance 1 day ago
    Up 3% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    MLYS Chart by TradingView
    Basic chart:

    Profile

    Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Hypertension Cardiovascular Disease Treatment Of Hypertension

    Is MLYS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 13 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q1 2024 Earnings Call Transcript
    May 13 We Think Mineralys Therapeutics (NASDAQ:MLYS) Can Afford To Drive Business Growth
    May 11 Mineralys Therapeutics, Inc. (MLYS) Q1 2024 Earnings Call Transcript
    May 9 Mineralys Therapeutics GAAP EPS of -$0.70 misses by $0.03
    May 9 Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    May 6 Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
    May 2 Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
    Apr 5 Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
    Apr 2 Goldman starts Mineralys at buy, cites upcoming drug data
    Mar 22 Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript
    See more MLYS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.44
    52 Week Low 5.86
    Average Volume 127,516
    200-Day Moving Average 10.89
    50-Day Moving Average 12.67
    20-Day Moving Average 13.04
    10-Day Moving Average 12.53
    Average True Range 0.60
    RSI (14) 50.74
    ADX 15.32
    +DI 24.50
    -DI 19.84
    Chandelier Exit (Long, 3 ATRs) 13.19
    Chandelier Exit (Short, 3 ATRs) 13.50
    Upper Bollinger Bands 14.43
    Lower Bollinger Band 11.66
    Percent B (%b) 0.4
    BandWidth 21.27
    MACD Line -0.10
    MACD Signal Line -0.03
    MACD Histogram -0.072
    Fundamentals Value
    Market Cap 524.91 Million
    Num Shares 41.1 Million
    EPS -1.38
    Price-to-Earnings (P/E) Ratio -9.25
    Price-to-Sales 0.00
    Price-to-Book 2.18
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 13.46
    Resistance 3 (R3) 13.40 13.10 13.35
    Resistance 2 (R2) 13.10 12.93 13.14 13.31
    Resistance 1 (R1) 12.94 12.82 13.02 13.00 13.27
    Pivot Point 12.64 12.64 12.69 12.68 12.64
    Support 1 (S1) 12.48 12.47 12.56 12.54 12.27
    Support 2 (S2) 12.18 12.36 12.22 12.23
    Support 3 (S3) 12.02 12.18 12.20
    Support 4 (S4) 12.08